机译:miR-424(322)/ 503是乳腺癌肿瘤抑制器,其损失促进抗化疗抗性
Icahn Sch Med Mt Sinai Dept Pathol New York NY 10029 USA;
Icahn Sch Med Mt Sinai Dept Pathol New York NY 10029 USA;
Aix Marseille Univ Inst Paoli Calmettes Ctr Rech Cancerol Marseille F-13009 Marseille France;
St Jude Childrens Res Hosp Kay Res &
Care Ctr IA6053 Memphis TN 38105 USA;
Columbia Univ Herbert Irving Comprehens Canc Ctr Ctr Computat Biol &
Bioinformat Dept Syst Biol;
Icahn Sch Med Mt Sinai Dept Pathol New York NY 10029 USA;
Icahn Sch Med Mt Sinai Dept Pathol New York NY 10029 USA;
Aix Marseille Univ Inst Paoli Calmettes Ctr Rech Cancerol Marseille F-13009 Marseille France;
Icahn Sch Med Mt Sinai Black Family Stem Cell Inst Dept Cell Dev &
Regenerat Biol New York NY;
Icahn Sch Med Mt Sinai Dept Pathol New York NY 10029 USA;
Aix Marseille Univ Inst Paoli Calmettes Ctr Rech Cancerol Marseille F-13009 Marseille France;
Icahn Sch Med Mt Sinai Dept Pathol New York NY 10029 USA;
Icahn Sch Med Mt Sinai Dept Pathol New York NY 10029 USA;
chemoresistance; breast cancer; microRNA; tumor suppressor;
机译:miR-424(322)/ 503是乳腺癌肿瘤抑制器,其损失促进抗化疗抗性
机译:乳腺癌转移抑制因子1的缺失通过增加趋化因子受体4的表达促进卵巢癌细胞的转移
机译:在分离的无细胞循环肿瘤DNA上可检测到的肿瘤抑制基因杂合性丧失可指示乳腺癌进展
机译:克服胰腺癌的治疗抗性不是PDT和化学疗法的简单组合:在3D肿瘤模型中评估PDT-化学疗法的组合
机译:转录因子REST的丧失会以LIN28依赖性的方式促进乳腺癌的致瘤性,并改变体内肿瘤生长的雌激素需求。
机译:miR-424(322)/ 503是一种乳腺癌肿瘤抑制因子其丢失会增强对化学疗法的抵抗力
机译:透明质酸-CD44与蛋白激酶Cϵ的相互作用促进了干细胞标记物Nanog的致癌信号传递和MicroRNA-21的产生,导致肿瘤抑制蛋白PDCD4的下调,抗凋亡和乳腺癌细胞对化疗的耐药性*